The generic name for Xeljanz is tofacitinib [1].
What is tofacitinib used to treat?
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat several autoimmune conditions [1]. These include:
* Rheumatoid arthritis (RA) [1]
* Psoriatic arthritis (PsA) [1]
* Ulcerative colitis (UC) [1]
* Polyarticular course of juvenile idiopathic arthritis (pcJIA) [1]
How does tofacitinib work?
Tofacitinib works by blocking the action of Janus kinases (JAKs), which are enzymes involved in the signaling pathways that promote inflammation [1]. By inhibiting these pathways, tofacitinib reduces inflammation and the symptoms associated with autoimmune diseases.
When did tofacitinib's patents expire?
Patent information for drugs is complex and can involve multiple patents covering different aspects of the drug, such as its composition of matter, manufacturing process, and methods of use. To find the most up-to-date and specific patent expiration dates for tofacitinib, it is best to consult specialized databases. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines [2].
What are the risks associated with tofacitinib?
Tofacitinib carries several serious risks, including [1]:
* Serious infections, such as tuberculosis and invasive fungal, bacterial, viral, and other opportunistic infections.
* Increased risk of blood clots (venous thromboembolism), stroke, heart attack, and death.
* Increased risk of certain cancers, including lymphoma and lung cancer.
* Increased risk of death in patients 50 years and older with at least one cardiovascular risk factor treated with a JAK inhibitor compared to TNF inhibitors.
* Tuberculosis and other serious infections.
* Shingles (herpes zoster).
* A hole in the stomach or intestines (perforation).
* Increased cholesterol levels.
* Decreased blood counts.
What are the alternatives to tofacitinib?
Treatment options for autoimmune diseases vary depending on the specific condition and its severity. Alternatives to tofacitinib may include other classes of drugs, such as:
* Other JAK inhibitors [1]
* Biologic disease-modifying antirheumatic drugs (bDMARDs) like TNF inhibitors [1]
* Non-biologic disease-modifying antirheumatic drugs (non-DMARDs) [1]
How does tofacitinib compare to other treatments?
Tofacitinib is a JAK inhibitor and offers a different mechanism of action compared to other treatment classes like TNF inhibitors. Clinical studies evaluate the efficacy and safety profiles of these different drug classes to inform treatment decisions for individual patients [1].
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer Inc. [1].
What is the cost of tofacitinib?
The cost of tofacitinib (Xeljanz) can vary significantly based on factors such as insurance coverage, pharmacy, dosage, and whether generic versions are available. For the most accurate pricing information, individuals should consult their healthcare provider or pharmacist, and explore patient assistance programs that may be offered by the manufacturer.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205940s042,209441s011,209442s011,209555s010lbl.pdf
[2] https://www.drugpatentwatch.com/